Product Description
Haim Bio is developing NYH-100P as a treatment for advanced solid tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04262739)
Mechanisms of Action: COMPLEX I Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Haim Bio
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04262739 |
HBCR-GP-01 | P1 |
Unknown status |
Oncology Solid Tumor Unspecified |
2021-12-01 |
50% |
2022-04-06 |
Recent News Events
Date |
Type |
Title |
|---|